Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effects of elecoglipron compared with a placebo in adults with chronic kidney disease CKD, including those with and without type 2 diabetes mellitus T2DM. This Phase III, randomized, double-blind, placebo-controlled study includes participants who are receiving standard care treatments for CKD, including the SGLT2 inhibitor dapagliflozin. The study aims to determine whether elecoglipron can reduce the risk of kidney function decline, end-stage kidney disease, and mortality. Participants will be randomly assigned to receive either elecoglipron tablets or matching placebo tablets once daily. The study is multicenter and involves parallel groups. The treatment period and evaluation are event-driven and may last up to 4.5 years. Both study groups will continue their background therapies for CKD alongside the study medication or placebo. During the study, participants will be monitored regularly to assess kidney function, cardiovascular events, and overall health outcomes, including mortality. Researchers will measure sustained declines in estimated glomerular filtration rate eGFR, occurrence of end-stage kidney disease, cardiovascular death, heart failure hospitalizations, and other related outcomes. The study includes safety monitoring throughout the trial, which is expected to last until October 2030, with participant involvement potentially extending up to 4.5 years.
Actively Recruiting
Researchers are evaluating the adherence, persistence, and effectiveness of PCSK9 inhibitors in treating hypercholesterolemia among a real-life Italian population. This observational study focuses on patients receiving these medications to better understand treatment patterns and outcomes outside of controlled clinical trials. Participants in this study are patients with hyperlipidemia who are currently treated with PCSK9 inhibitors, specifically Repatha evolocumab or Praluent alirocumab, administered by injection. The study observes these patients without altering their treatment, collecting data over time to assess how well patients stick to their treatment plans and how effective the medications are. During the study, researchers will gather information every six months about treatment adherence, persistence, and efficacy. They will also monitor safety and analyze results within different patient subgroups. Participation includes regular assessments of medication use and health outcomes, with the study continuing until March 31, 2030.
Actively Recruiting
Researchers are collecting and evaluating long-term clinical and radiographic data to better understand the safety and performance of shoulder arthroplasty over time. This observational study focuses on various shoulder conditions including osteoarthritis, rotator cuff tears, rheumatoid arthritis, and fractures. The study will follow participants for a minimum of 10 years to gather extensive outcome information. Participants include those who have undergone or are indicated for shoulder arthroplasty. The study observes outcomes without administering specific treatments, tracking results through clinical assessments and imaging over time. There is no early limit on follow-up duration, allowing for a comprehensive long-term evaluation of the shoulder implants function. During the study, participants will undergo annual assessments using several scores such as the Constant score, ASES, Oxford Score, TESS, and MSTS. These measures evaluate shoulder function and condition throughout the study period. Participants are expected to comply with pre- and postoperative visit requirements, and their progress will be monitored for at least 10 years to assess the implants longevity and safety.